Affymax Announces Third Quarter 2012 Financial Results Teleconference and Webcast

Business Wirevia The Motley Fool
Updated

Affymax Announces Third Quarter 2012 Financial Results Teleconference and Webcast

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (NAS: AFFY) today announced that it will host a teleconference and webcast with management to provide a general business overview, as well as to discuss its third quarter 2012 financial results on Thursday, November 8, 2012 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Financial results for the quarter ended September 30, 2012 will be released after market close on November 8, 2012.

Interested parties can listen to the live teleconference by dialing (866) 393-1565 from the U.S. or +1 (973) 409-9608 for international callers. Individuals may access the live audio webcast at http://www.investors.affymax.com/events.cfm. A replay of the webcast will be available on the Company's website for 30 days following the live event.


About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California. Affymax's mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses.

The company's first marketed product, OMONTYS® (peginesatide) Injection, was approved by the U.S. Food and Drug Administration (FDA) in March 2012. For additional information, please visit www.affymax.com.



Affymax, Inc.
Alexandra Santos, 650-812-8961
Associate Director, Corporate Communications

KEYWORDS: United States North America California

INDUSTRY KEYWORDS:

The article Affymax Announces Third Quarter 2012 Financial Results Teleconference and Webcast originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement